# Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

> **NCT05993299** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **USWM, LLC (dba US WorldMeds)** · enrollment: 7 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Letetresgene autoleucel
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT05993299
- **Lead sponsor:** USWM, LLC (dba US WorldMeds)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-31
- **Primary completion:** 2022-10-12
- **Final completion:** 2026-07-01
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05993299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05993299, "Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05993299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*